ES2663869T3 - Procedimiento para la síntesis de análogos de la grelina - Google Patents

Procedimiento para la síntesis de análogos de la grelina Download PDF

Info

Publication number
ES2663869T3
ES2663869T3 ES12840868.9T ES12840868T ES2663869T3 ES 2663869 T3 ES2663869 T3 ES 2663869T3 ES 12840868 T ES12840868 T ES 12840868T ES 2663869 T3 ES2663869 T3 ES 2663869T3
Authority
ES
Spain
Prior art keywords
bal
apc
trp
nal
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12840868.9T
Other languages
English (en)
Inventor
Fionn Hurley
Katarzyna WEGNER
Patrick Foley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Manufacturing Ireland Ltd
Original Assignee
Ipsen Manufacturing Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Manufacturing Ireland Ltd filed Critical Ipsen Manufacturing Ireland Ltd
Application granted granted Critical
Publication of ES2663869T3 publication Critical patent/ES2663869T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/063—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para la síntesis de un péptido terapéutico mediante el uso de la química de Fmoc en fase sólida por etapas, que comprende las etapas de: (a) hacer hinchar la resina de Fmoc-Sieber (también denominada resina de amida de Sieber o resina de amida de Fmoc-Sieber) en un solvente aprótico dipolar; (b) desproteger el grupo Fmoc con una solución de piperidina en un solvente aprótico dipolar; (c) lavar la resina después de la desprotección del Fmoc con un solvente aprótico dipolar; (d) activar los aminoácidos-Fmoc para la conjugación a la resina desprotegida al disolver el aminoácido-Fmoc y el reactivo o reactivos de conjugación en un solvente aprótico dipolar, y, a continuación, añadir una base y agitar; (e) cargar la solución de aminoácido-Fmoc activado en la resina en el reactor; (f) conjugar el aminoácido-Fmoc activado con el uso de hexafluorofosfato de 2-(6-cloro-1H-benzotriazol-1-il)-1,1,3,3- tetrametilaminio (HCTU) o de tetrafluoroborato de 2-(1H-benzotriazol-1-il)-1,1,3,3-tetrametiluronio (TBTU)/1- hidroxibenzotriazol (HOBt) con una base en un solvente aprótico dipolar como reactivo de conjugación; (g) lavar la resina después de cada conjugación de aminoácido-Fmoc; (h) repetir las etapas (b) a (g) hasta que se forme un péptido; (i) escindir el péptido deseado de la resina mientras que se desprotegen simultáneamente las cadenas laterales de los aminoácidos con un cóctel de escisión; (j) filtrar la mezcla de escisión desde la resina; y (k) hacer que se evaporen los filtrados, y precipitar y purificar parcialmente el producto bruto desde la solución concentrada con un solvente orgánico para producir un péptido parcialmente purificado. en donde dicho péptido es un análogo de la grelina de fórmula (I) R1-A1-A2-A3-A4-A5-R2 (I) en donde A1 es Aib, Apc o Inp; A2 es D-Bal, D-Bip, D-Bpa, D-Dip, D-1-Nal, D-2-Nal, D-Ser(Bzl), o D-Trp; A3 es D-Bal, D-Bip, D-Bpa, D-Dip, D-1-Nal, D-2-Nal, D-Ser(Bzl), o D-Trp; A4 es 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); A5 es Apc, Dab, Dap, Lys, Orn, o delecionado; R1 es hidrógeno; y R2 es OH o NH; con tal de que cuando A5 es Dab, Dap, Lys u Orn, entonces: A2 es D-Bip, D-Bpa, D-Dip o D-Bal; o A3 es D-Bip, D-Bpa, D-Dip o D-Bal; o A4 es 2Thi, 3Thi, Taz, 2Fua, 2Pal, 3Pal, 4Pal, Orn, Thr(Bzl), o Pff; cuando A5 está delecionado, entonces: A3 es D-Bip, D-Bpa o D-Dip; o A4 es 2Fua, Pff, Taz, o Thr(Bzl); o A1 es Apc y - A2 es D-Bip, D-Bpa, D-Dip o D-Bal; o A3 es D-Bip, D-Bpa, D-Dip o D-Bal; o A4 es 2Thi, 3Thi, Orn, 2Pal, 3Pal, o 4Pal.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
5
10
15
20
25
30
35
Figura 2: gráfico en el que se representa la reproducibilidad del rendimiento de la síntesis en una escala de 2 g a 2200 g cuando se utiliza la resina de amida de Sieber para la síntesis de un péptido de 5 aminoácidos. Tal y como está descrito, se consiguió constantemente un rendimiento de síntesis de aproximadamente el 80% para cada escala.
Figura 3: gráfico en el que se representa el coste relativo basado en el material empleado para la síntesis de un péptido de 8 aminoácidos y un péptido de 30 aminoácidos mediante el uso de una resina de amida de Rink frente a una resina de amida de Sieber. El coste relativo basado en los materiales utilizados para esos péptidos sintetizados mediante una resina de amida de Rink para un péptido de 8 aminoácidos y un péptido de 30 aminoácidos está representado por las barras superiores, mientras que el coste relativo para el mismo péptido con el uso de una resina de amida de Sieber está representado por las barras inferiores para cada péptido. Tal y como está descrito, el coste relativo de utilizar una resina de amida de Sieber es menor que el de una resina de amida de Rink.
La mayoría de las etapas de síntesis en fase sólida por etapas necesitan usar una resina de poliestireno para la síntesis de las amidas peptídicas. Las resinas de amida de Rink se utilizan en una síntesis de péptidos en fase sólida para preparar las amidas peptídicas mediante la utilización de aminoácidos protegidos con Fmoc.
La conjugación del primer aminoácido se puede conseguir con los métodos típicos de formación de enlaces amida. La secuencia peptídica se ensambla en condiciones básicas o neutras sobre la resina de amida de Rink, y luego se escinde de la resina el péptido completado en condiciones ácidas. Típicamente, el péptido se escinde desde la resina de amida de Rink con TFA a más del 80% v/v (Stathopoulos, P.; Papas, S.; y Tsikaris, V., J. Pept. Sci., 2006,
12: 227-37). Los ácidos más fuertes o las concentraciones más elevadas de TFA algunas veces escinden parte del conector de Rink desde el soporte de poliestireno e introduce impurezas coloreadas en el producto escindido. Tal cual, para algunos péptidos, el rendimiento de la síntesis con la resina de amida de Rink es tradicionalmente bajo. Ejemplos de resinas de Rink son:
imagen9
La inestabilidad del conector de la resina «supersensible a ácido» o «hipersensible a ácido» a bajas concentraciones de ácido permite que se liberen de la resina los péptidos totalmente protegidos. Típicamente, se necesita del 1 al 5% v/v de TFA para la escisión de los péptidos. Con la excepción de la disminución de la potencia del ácido necesario para la escisión, estas resinas son similares a las resinas de amida de Rink, a saber, son una matriz de poliestireno con un tamaño de perla similar y con una capacidad de carga similar. Como tales, estas resinas son útiles para la síntesis convergente que emplea la misma química de Fmoc con respecto a la carga de primer resto y al acoplamiento de los restos posteriores.
La resina de amida de Sieber, un ejemplo de resinas «supersensibles a ácido» (Sieber, P., Tetrahedron Lett., 1987, 28(19): 2107-10), se utiliza principalmente para la síntesis de amidas peptídicas que conservan los grupos protectores de la cadena lateral, entre ellos, pero sin limitarse a ellos, tert-butiloxicarbonilo (Boc) y éter de tert-butilo (tBu) cuando se utilizan con concentraciones bajas de ácido trifluoroacético (TFA) (1-5% v/v) en el cóctel de escisión.
10
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
H-Apc-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Pff-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-Apc-NH2
5 H-Apc-D-2-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-NH2 H-Apc-D-2-Nal-D-Trp-2-Pal-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Lys-NH2
10 H-Apc-D-2-Nal-D-Trp-3-Pal-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-NH2 H-Apc-D-2-Nal-D-Trp-4-Pal-NH2
15 H-Apc-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Lys-NH2 H-Apc-D-2-Nal-D-Trp-Pff-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Lys-NH2
20 H-Apc-D-Bal-D-Bal-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Fua-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Fua-NH2 H-Apc-D-Bal-D-Bal-2-Pal-NH2 H-Apc-D-Bal-D-Bal-2-Thi-Apc-NH2
25 H-Apc-D-Bal-D-Bal-2-Thi-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Thi-NH2 H-Apc-D-Bal-D-Bal-3-Pal-NH2 H-Apc-D-Bal-D-Bal-3-Thi-Apc-NH2 H-Apc-D-Bal-D-Bal-3-Thi-Lys-NH2
30 H-Apc-D-Bal-D-Bal-3-Thi-NH2 H-Apc-D-Bal-D-Bal-4-Pal-NH2 H-Apc-D-Bal-D-Bal-Pff-Apc-NH2 H-Apc-D-Bal-D-Bal-Pff-Lys-NH2 H-Apc-D-Bal-D-Bal-Pff-NH2
35 H-Apc-D-Bal-D-Bal-Phe-Apc-NH2 H-Apc-D-Bal-D-Bal-Phe-Lys-NH2 H-Apc-D-Bal-D-Bal-Phe-NH2
22
H-Apc-D-Bal-D-Bal-Taz-Apc-NH2 H-Apc-D-Bal-D-Bal-Taz-Lys-NH2 H-Apc-D-Bal-D-Bal-Taz-NH2 H-Apc-D-Bal-D-Trp-2-Fua-Apc-NH2
5 H-Apc-D-Bal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-Bal-D-Trp-2-Fua-NH2 H-Apc-D-Bal-D-Trp-2-Pal-NH2 H-Apc-D-Bal-D-Trp-3-Pal-NH2 H-Apc-D-Bal-D-Trp-3-Thi-Apc-NH2
10 H-Apc-D-Bal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-Bal-D-Trp-3-Thi-NH2 H-Apc-D-Bal-D-Trp-4-Pal-NH2 H-Apc-D-Bal-D-Trp-Pff-Apc-NH2 H-Apc-D-Bal-D-Trp-Pff-Lys-NH2
15 H-Apc-D-Bal-D-Trp-Pff-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-NH2 H-Inp-D-1-Nal-D-B al-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-3-Thi-Lys-NH2
20 H-Inp-D-1-Nal-D-Bal-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Pff-NH2 H-Inp-D-1-Nal-D-Bal-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Taz-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Taz-NH2
25 H-Inp-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Lys-NH2
30 H-Inp-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Pff-NH2 H-Inp-D-1-Nal-D-Trp-Taz-NH2 H-Inp-D-2-Nal-D-Trp-2-Fua-Apc-NH2
35 H-Inp-D-2-Nal-D-Trp-2-Fua-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-Apc-NH2
23
imagen21
H-Inp-D-Bip-D-Trp-Pff-NH2 H-Inp-D-Bip-D-Trp-Taz-Lys-NH2 H-Inp-D-Bip-D-Trp-Taz-NH2 H-Inp-D-1-Nal-D-Trp-3-Pal-Lys-NH2
5 H-Inp-D-2-Nal-D-Trp-4-Pal-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Orn-Lys-NH2 H-Inp-D-Bip-D-Trp-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Thr(Bzl)-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Pff-Lys-NH2
10 H-Inp-D-2-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Taz-Lys-NH2 H-Inp-D-Dip-D-Trp-Phe-Lys-NH2 H-Inp-D-Bpa-D-Trp-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Bpa-Phe-Lys-NH2
15 H-Inp-D-2-Nal-D-Trp-Thr(Bzl)-NH2 H-Inp-D-2-Nal-D-Trp-Pff-NH2 H-Inp-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-2-Nal-D-Dip-Phe-NH2 H-Inp-D-2-Nal-D-Trp-3-Pal-Lys-NH2
20 H-Inp-D-Bal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-Bal-D-Trp-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Phe-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Phe-Apc-NH2
25 H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Taz-Lys-NH2 H-Inp-D-Bal-D-Trp-Taz-Lys-NH2
30 H-Apc-D-1-Nal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Trp-2-Thi-Lys-NH2 H-Apc-D-Bal-D-Trp-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Phe-Apc-NH2
35 H-Apc-D-Bal-D-Trp-Phe-Apc-NH2 H-Apc-D-1-Nal-D-1-Nal-Phe-Apc-NH2 H-Apc-D-1-Nal-D-2-Nal-Phe-Apc-NH2
25
imagen22
H-Apc-D-Bal-D-Bal-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Lys-NH2
5 H-Inp-D-1-Nal-D-Bal-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Bal-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-3-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Taz-Lys-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-Lys-NH2
10 H-Inp-D-1-Nal-D-Bal-Pff-Lys-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-Taz-Apc-NH2 H-Inp-D-2-Nal-D-Trp-2-Fua-Apc-NH2
15 H-Inp-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-Lys-NH2
20 H-Apc-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Lys-NH2
25 H-Apc-D-2-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-Bip-D-Trp-2-Thi-Lys-NH2 H-Inp-D-Bip-D-Trp-3-Thi-Lys-NH2 H-Inp-D-Bip-D-Trp-Taz-Lys-NH2
30 H-Inp-D-Bip-D-Trp-2-Fua-Lys-NH2 H-Inp-D-Bip-D-Trp-Pff-Lys-NH2 H-Inp-D-Bip-D-Bal-2-Thi-Lys-NH2 H-Inp-D-Bip-D-Bal-3-Thi-Lys-NH2 H-Inp-D-Bip-D-Bal-Taz-Lys-NH2
35 H-Inp-D-Bip-D-Bal-2-Fua-Lys-NH2 H-Inp-D-Bip-D-Bal-Pff-Lys-NH2 H-Apc-D-Bal-D-Trp-3-Thi-Apc-NH2
27
H-Apc-D-Bal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Trp-Pff-Apc-NH2 H-Apc-D-Bal-D-Bal-Phe-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Thi-Apc-NH2
5 H-Apc-D-Bal-D-Bal-3-Thi-Apc-NH2 H-Apc-D-Bal-D-Bal-Taz-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Bal-Pff-Apc-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-Apc-NH2
10 H-Apc-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Apc-NH2
15 H-Apc-D-2-Nal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-Bal-D-Trp-Taz-NH2 H-Inp-D-Bal-D-Trp-2-Fua-NH2 H-Inp-D-Bal-D-Trp-Pff-NH2
20 H-Apc-D-Bal-D-Trp-3-Thi-NH2 H-Apc-D-Bal-D-Trp-2-Fua-NH2 H-Apc-D-Bal-D-Trp-Pff-NH2 H-Apc-D-Bal-D-Trp-4-Pal-NH2 H-Apc-D-Bal-D-Trp-3-Pal-NH2
25 H-Apc-D-Bal-D-Trp-2-Pal-NH2 H-Inp-D-Bal-D-Bal-Taz-NH2 H-Inp-D-Bal-D-Bal-2-Fua-NH2 H-Inp-D-Bal-D-Bal-Pff-NH2 H-Apc-D-Bal-D-Bal-Phe-NH2
30 H-Apc-D-Bal-D-Bal-2-Thi-NH2 H-Apc-D-Bal-D-Bal-3-Thi-NH2 H-Apc-D-Bal-D-Bal-Taz-NH2 H-Apc-D-Bal-D-Bal-2-Fua-NH2 H-Apc-D-Bal-D-Bal-Pff-NH2
35 H-Apc-D-Bal-D-Bal-4-Pal-NH2 H-Apc-D-Bal-D-Bal-3-Pal-NH2 H-Apc-D-Bal-D-Bal-2-Pal-NH2
28
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES12840868.9T 2011-12-23 2012-12-21 Procedimiento para la síntesis de análogos de la grelina Active ES2663869T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580089P 2011-12-23 2011-12-23
US201161580089P 2011-12-23
PCT/IB2012/003056 WO2013093639A1 (en) 2011-12-23 2012-12-21 Process for the synthesis of therapeutic peptides

Publications (1)

Publication Number Publication Date
ES2663869T3 true ES2663869T3 (es) 2018-04-17

Family

ID=48095921

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12840868.9T Active ES2663869T3 (es) 2011-12-23 2012-12-21 Procedimiento para la síntesis de análogos de la grelina

Country Status (14)

Country Link
US (2) US9475837B2 (es)
EP (1) EP2794634B1 (es)
JP (1) JP6192657B2 (es)
KR (1) KR101996700B1 (es)
CN (1) CN104080795A (es)
AU (1) AU2012356321B2 (es)
BR (1) BR112014015275A2 (es)
CA (1) CA2856257A1 (es)
ES (1) ES2663869T3 (es)
HK (1) HK1202125A1 (es)
MX (1) MX350536B (es)
RU (1) RU2625793C2 (es)
UA (1) UA115542C2 (es)
WO (1) WO2013093639A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1937262T3 (pl) 2005-09-29 2019-10-31 Ipsen Pharma Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
CA2907521C (en) 2013-03-21 2021-04-13 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2015134567A1 (en) * 2014-03-04 2015-09-11 Rhythm Pharmaceuticals, Inc. Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
CN110317188B (zh) * 2018-03-29 2023-01-17 深圳翰宇药业股份有限公司 化合物及其制备方法和应用
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
CN113330021A (zh) 2019-01-24 2021-08-31 帝斯曼知识产权资产管理有限公司 肽沉淀方法
WO2020167010A1 (ko) * 2019-02-15 2020-08-20 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
WO2021067897A1 (en) * 2019-10-04 2021-04-08 Tiburio Therapeutics Inc. Storage stable somatostatin-dopamine chimeric compounds and salt forms thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5117009A (en) * 1990-08-31 1992-05-26 University Of Minnesota Xanthenylamide handle for use in peptide synthesis
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
JP3996897B2 (ja) 2001-06-08 2007-10-24 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチン−ドーパミンキメラ類似体
JP4276462B2 (ja) * 2002-04-11 2009-06-10 アスビオファーマ株式会社 修飾ペプチドの製造方法
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
KR20070102756A (ko) * 2003-04-11 2007-10-19 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 소마토스타틴-도파민 키메라 유사체
US8138218B2 (en) * 2005-07-22 2012-03-20 Ipsen Pharma S.A.S. Growth hormone secretagogues
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
WO2007139589A1 (en) * 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
CN101538316B (zh) 2009-01-13 2012-09-05 深圳翰宇药业股份有限公司 一种固相法制备Eptifibatide的方法
US20100311946A1 (en) * 2009-06-03 2010-12-09 Mallinckrodt Inc. Solid Phase Peptide for the Production of Goserelin

Also Published As

Publication number Publication date
MX2014007263A (es) 2014-08-01
JP2015504045A (ja) 2015-02-05
RU2625793C2 (ru) 2017-07-19
HK1202125A1 (en) 2015-09-18
EP2794634A1 (en) 2014-10-29
BR112014015275A8 (pt) 2017-06-13
WO2013093639A1 (en) 2013-06-27
BR112014015275A2 (pt) 2017-06-13
UA115542C2 (uk) 2017-11-27
US20170137489A1 (en) 2017-05-18
KR20140113696A (ko) 2014-09-24
AU2012356321A1 (en) 2014-07-17
MX350536B (es) 2017-09-08
EP2794634B1 (en) 2018-01-24
KR101996700B1 (ko) 2019-07-04
JP6192657B2 (ja) 2017-09-06
RU2014130277A (ru) 2016-02-20
AU2012356321B2 (en) 2015-09-17
US9475837B2 (en) 2016-10-25
CA2856257A1 (en) 2013-06-27
US20150045534A1 (en) 2015-02-12
CN104080795A (zh) 2014-10-01

Similar Documents

Publication Publication Date Title
ES2663869T3 (es) Procedimiento para la síntesis de análogos de la grelina
EP2632935B1 (en) Process for the manufacture of degarelix and its intermediates
DK2632934T3 (en) Process for the preparation of Degarelix and its intermediates
JP5199126B2 (ja) グルカゴン様ペプチドの合成
AR062801A2 (es) Peptidos liberadores de la hormona de crecimiento
US20100184952A1 (en) Method for selective removal of dibenzofulvene derivative
ES2938734T3 (es) Procedimiento para la fabricación de análogos de GLP-1
ES2890676T3 (es) Procedimiento para la producción de D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
WO2010089757A3 (en) An improved process for synthesis of cyclic octapeptide
ES2869430T3 (es) Procedimiento para preparar D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
BR112015031679B1 (pt) Método para a preparação de um peptídeo contendo arginina ou homo-arginina
CN116507763A (zh) 抑制由二酮哌嗪形成导致的缺损的肽合成方法
RU2592282C1 (ru) Способ получения нонапептидов
Jobin et al. Toward solid-phase peptide fragment ligation by a traceless-Ugi multicomponent approach
Olma et al. Synthesis and binding properties of deltorphin I analogues containing (R) and (S)-α-hydroxymethylnaphtylalanine.